Oramed Pharmaceuticals (ORMP) Short Interest Ratio & Short Volume $2.30 -0.06 (-2.54%) As of 01:54 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals Short Interest DataOramed Pharmaceuticals (ORMP) has a short interest of 664,600 shares, representing 1.91% of the float (the number of shares available for trading by the public). This marks a 7.89% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.6, indicating that it would take 2.6 days of the average trading volume of 157,778 shares to cover all short positions.Current Short Interest664,600 sharesPrevious Short Interest616,000 sharesChange Vs. Previous Month+7.89%Dollar Volume Sold Short$1.59 millionShort Interest Ratio2.6 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares40,312,000 sharesShort Percent of Float1.91%Today's Trading Volume20,043 sharesAverage Trading Volume157,778 sharesToday's Volume Vs. Average13% Short Selling Oramed Pharmaceuticals? Sign up to receive the latest short interest report for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartORMP Short Interest Over TimeORMP Days to Cover Over TimeORMP Percentage of Float Shorted Over Time Remove Ads Oramed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2025664,600 shares $1.59 million +7.9%1.9%2.6 $2.39 2/28/2025616,000 shares $1.29 million +6.9%1.8%2.2 $2.09 2/15/2025576,400 shares $1.38 million +149.0%1.7%2.1 $2.40 1/31/2025231,500 shares $518,560.00 -6.7%N/A0.9 $2.24 1/15/2025248,200 shares $580,788.00 +2.4%N/A1.6 $2.34 12/31/2024242,300 shares $586,366.00 -16.9%N/A1.7 $2.42 12/15/2024291,400 shares $719,758.00 -2.7%N/A2.2 $2.47 11/30/2024299,500 shares $709,815.00 -4.6%N/A2.4 $2.37 11/15/2024313,900 shares $699,997.00 +4.6%N/A3.1 $2.23 10/31/2024300,000 shares $714,000.00 +0.5%N/A3 $2.38 Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/15/2024298,500 shares $701,475.00 -12.3%N/A3 $2.35 9/30/2024340,400 shares $830,576.00 -4.0%N/A3.4 $2.44 9/15/2024354,400 shares $882,456.00 -2.4%N/A2.9 $2.49 8/31/2024363,200 shares $868,048.00 +53.0%N/A2.7 $2.39 8/15/2024237,400 shares $557,890.00 -14.6%N/A1.7 $2.35 7/31/2024278,100 shares $709,155.00 -16.9%N/A2.1 $2.55 7/15/2024334,700 shares $846,791.00 -36.7%N/A2.7 $2.53 6/30/2024529,100 shares $1.36 million +13.1%N/A4 $2.57 6/15/2024467,800 shares $1.05 million +63.3%N/A4 $2.25 5/31/2024286,500 shares $624,570.00 -5.9%N/A2.6 $2.18 5/15/2024304,600 shares $727,994.00 -6.2%N/A2.5 $2.39 4/30/2024324,600 shares $753,072.00 -11.7%N/A2.2 $2.32 4/15/2024367,600 shares $889,592.00 -37.0%N/A2.2 $2.42 3/31/2024583,900 shares $1.70 million +20.6%N/A3.3 $2.92 3/15/2024484,000 shares $1.41 million -3.3%N/A2.6 $2.92 2/29/2024500,700 shares $1.65 million -27.6%N/A2.5 $3.29 2/15/2024691,600 shares $2.17 million +76.0%N/A3.6 $3.14 1/31/2024393,000 shares $1.18 million +5.3%N/A2.1 $3.00 1/15/2024373,200 shares $873,288.00 +17.4%N/A1.8 $2.34 12/31/2023318,000 shares $734,580.00 -15.4%N/A1.6 $2.31 12/15/2023376,000 shares $827,200.00 -10.0%N/A2 $2.20 11/30/2023417,800 shares $927,516.00 -10.3%N/A2.4 $2.22 11/15/2023465,900 shares $959,754.00 +3.6%N/A2.6 $2.06 10/31/2023449,800 shares $823,134.00 -23.6%N/A2.5 $1.83 10/15/2023588,400 shares $1.28 million -2.2%N/A3.5 $2.18 9/30/2023601,800 shares $1.57 million +6.3%N/A3.4 $2.61 9/15/2023566,200 shares $1.72 million +25.8%N/A2.8 $3.04 8/31/2023450,000 shares $1.48 million -13.7%N/A1.8 $3.28 8/15/2023521,600 shares $1.63 million +4.0%N/A1.4 $3.13 7/31/2023501,400 shares $1.70 million -25.9%N/A0.6 $3.39While Markets Slide, These "Genesis Cog" Trades Are Up Double-Digits (Ad)While most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.Click here to discover how the Genesis Cog works in falling markets 7/15/2023677,000 shares $2.17 million -15.1%N/A0.8 $3.21 6/30/2023797,800 shares $2.86 million -6.5%N/A0.9 $3.58 6/15/2023852,900 shares $3.45 million -7.6%N/A0.9 $4.04 5/31/2023923,300 shares $3.73 million +89.9%N/A1 $4.04 5/15/2023486,300 shares $1.52 million -6.6%N/A0.5 $3.13 4/30/2023520,400 shares $1.18 million -33.4%N/A0.7 $2.27 4/15/2023781,200 shares $1.75 million -1.0%N/A0.9 $2.24 3/31/2023789,300 shares $1.72 million -19.9%N/A0.5 $2.18 3/15/2023985,700 shares $1.99 million -7.0%N/A0.6 $2.02 2/28/20231,060,000 shares $2.23 million +8.3%N/A0.6 $2.10 2/15/2023978,500 shares $2.15 million +3.4%N/A0.6 $2.20 1/31/2023946,000 shares $1.88 million -65.6%N/A0.6 $1.99 1/15/20232,750,000 shares $6.19 million -2.5%N/A2.1 $2.25 12/30/20222,820,000 shares $33.92 million +4.8%N/A6.9 $12.03 12/15/20222,690,000 shares $22.00 million -2.2%N/A9.1 $8.18 11/30/20222,750,000 shares $23.24 million -5.5%N/A10.5 $8.45 11/15/20222,910,000 shares $26.19 million -3.6%N/A10.9 $9.00 10/31/20223,020,000 shares $21.47 million +0.7%N/A11 $7.11 10/15/20223,000,000 shares $18.72 million -3.2%N/A9.4 $6.24 9/30/20223,100,000 shares $20.09 million +4.7%N/A3.7 $6.48 9/15/20222,960,000 shares $24.92 million -0.3%N/A2.3 $8.42 8/31/20222,970,000 shares $25.42 million -0.7%N/A2.2 $8.56 8/15/20222,990,000 shares $29.63 million -6.9%N/A2.1 $9.91 7/31/20223,210,000 shares $28.18 million -10.6%N/A2.1 $8.78 7/15/20223,590,000 shares $28.65 million +30.1%N/A2.3 $7.98 6/30/20222,760,000 shares $12.64 million -25.4%N/A1.8 $4.58 6/15/20223,700,000 shares $14.65 million +12.8%30.1%4.7 $3.96 5/31/20223,280,000 shares $15.19 million +1.6%N/A5.1 $4.63 5/15/20223,230,000 shares $14.76 million +26.2%N/A5.3 $4.57 4/30/20222,560,000 shares $13.16 million +15.8%N/A4.8 $5.14 4/15/20222,210,000 shares $15.16 million -6.8%N/A3.6 $6.86 3/31/20222,370,000 shares $20.50 million +4.9%N/A3.8 $8.65 3/15/20222,260,000 shares $20.05 million +2.7%N/A3.1 $8.87 2/28/20222,200,000 shares $22.66 million -2.2%N/A2.8 $10.30 2/15/20222,250,000 shares $26.15 million +2.3%N/A2.5 $11.62 1/31/20222,200,000 shares $19.71 million +9.5%N/A2.3 $8.96 1/15/20222,010,000 shares $22.21 million -9.1%N/A2.2 $11.05 12/31/20212,210,000 shares $31.56 million +10.0%N/A2.6 $14.28 12/15/20212,010,000 shares $30.33 million +122.9%N/A2.5 $15.09 11/30/2021901,600 shares $17.33 million -3.4%N/A1.1 $19.22 11/15/2021933,400 shares $26.28 million -3.5%N/A1.2 $28.16 10/29/2021967,400 shares $22.65 million -7.9%N/A1.2 $23.41 10/15/20211,050,000 shares $23.16 million -3.7%3.7%1.3 $22.06 9/30/20211,090,000 shares $23.96 million -2.7%3.8%1.2 $21.98 9/15/20211,120,000 shares $21.78 million -5.9%3.9%1.3 $19.45 8/31/20211,190,000 shares $23.42 million -13.8%4.2%1.5 $19.68 8/13/20211,380,000 shares $24.40 million -27.8%4.9%1.8 $17.68 7/30/20211,910,000 shares $27.10 million -14.7%6.9%2.8 $14.19 7/15/20212,240,000 shares $28.45 million -6.3%8.1%4.1 $12.70 6/30/20212,390,000 shares $31.98 million +10.7%8.9%4.7 $13.38Here’s how you could profit from Elon’s NVIDIA partnership (Ad)Elon Musk recently offered NVIDIA $1 billion... To buy a cluster of their cutting-edge GB200 AI chips. Why? Because Elon is quietly building the most powerful AI supercomputer on the planet. It's called "Project Colossus"...Don't know where to start investing in AI? Check out my latest investor briefing. 6/15/20212,160,000 shares $28.84 million -12.9%8.0%4.7 $13.35 5/28/20212,480,000 shares $28.57 million -0.8%9.6%3.8 $11.52 5/14/20212,500,000 shares $25.65 million +7.3%9.7%4 $10.26 4/30/20212,330,000 shares $25.33 million +4.5%9.1%3.4 $10.87 4/15/20212,230,000 shares $20.69 million +0.5%8.7%2.6 $9.28 3/31/20212,220,000 shares $22.44 million +22.7%9.0%2.7 $10.11 3/15/20211,810,000 shares $17.01 million +4.0%7.4%2.2 $9.40 2/26/20211,740,000 shares $15.57 million -4.4%7.1%2.6 $8.95 2/12/20211,820,000 shares $18.56 million +45.6%7.6%2 $10.20 1/29/20211,250,000 shares $8.74 million +54.8%5.3%1.5 $7.00 1/15/2021807,700 shares $3.60 million No Change3.8%1.3 $4.46 ORMP Short Interest - Frequently Asked Questions What is Oramed Pharmaceuticals' current short interest? Short interest is the volume of Oramed Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 664,600 shares of ORMP short. 1.91% of Oramed Pharmaceuticals' shares are currently sold short. Learn More on Oramed Pharmaceuticals' current short interest. What is a good short interest ratio for Oramed Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ORMP shares currently have a short interest ratio of 3.0. Learn More on Oramed Pharmaceuticals's short interest ratio. Which institutional investors are shorting Oramed Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Oramed Pharmaceuticals: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Oramed Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.91% of Oramed Pharmaceuticals' floating shares are currently sold short. Is Oramed Pharmaceuticals' short interest increasing or decreasing? Oramed Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 664,600 shares, an increase of 7.9% from the previous total of 616,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oramed Pharmaceuticals' short interest compare to its competitors? 1.91% of Oramed Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oramed Pharmaceuticals: Revance Therapeutics, Inc. (4.32%), ABIVAX Société Anonyme (2.47%), Humacyte, Inc. (25.48%), Aura Biosciences, Inc. (2.68%), Rapport Therapeutics (13.27%), Cartesian Therapeutics, Inc. (23.83%), Taysha Gene Therapies, Inc. (12.66%), Astria Therapeutics, Inc. (6.87%), Heron Therapeutics, Inc. (22.37%), Benitec Biopharma Inc. (0.93%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Oramed Pharmaceuticals stock? Short selling ORMP is an investing strategy that aims to generate trading profit from Oramed Pharmaceuticals as its price is falling. ORMP shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oramed Pharmaceuticals? A short squeeze for Oramed Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ORMP, which in turn drives the price of the stock up even further. How often is Oramed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORMP, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies Revance Therapeutics Short Interest Data ABIVAX Société Anonyme Short Interest Data Humacyte Short Interest Data Aura Biosciences Short Interest Data Rapport Therapeutics Short Interest Data Cartesian Therapeutics Short Interest Data Taysha Gene Therapies Short Interest Data Astria Therapeutics Short Interest Data Heron Therapeutics Short Interest Data Benitec Biopharma Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ORMP) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
